Sanacora, Gerard http://orcid.org/0000-0003-3722-8829
Colloca, Luana
Article History
First Online: 19 October 2023
Competing interests
: L.C. reports receiving grants from the National Institutes of Health; personal fees from the Veterans Health Administration, Chiesi, Averitas and Shionogi; and consulting fees from Pfizer outside of this article. G.S. reports receiving grants from Janssen, Merck, and Usona; and personal fees from Ancora, Aptinyx, Atai, Axsome Therapeutics, Biogen, Biohaven Pharmaceuticals, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Clexio, Cowen, Denovo Biopharma, ECR1, EMA Wellness, Engrail Therapeutics, Freedom Biosciences, Gilgamesh, Intra-Cellular Therapies, Janssen, KOA Health, Levo Therapeutics, Lundbeck, Merck, MiCure, Navitor Pharmaceuticals, Neurocrine Biosciences, Novartis, Noven Pharmaceuticals, Otsuka, Perception Neuroscience, Praxis Therapeutics, Relmada Therapeutics, Sage Pharmaceuticals, Seelos Pharmaceuticals, Valeant, Vistagen Therapeutics, and XW Lab outside of this article. G.S. also has a patent pending for a treatment method using a rapid-acting antidepressant and an mTOR inhibitor or immunosuppressant (held by Yale University).